ABSTRACT: Selagintamarlin A (1), a novel selaginellin analogue featuring the unique motif of 1H-2-benzopyran, a new selaginpulvilin E (2), together with eight known analogues were isolated from Selaginella tamariscina. Their structures were elucidated by extensive spectroscopic analyses. A plausible biosynthetic pathway of 1 was also postulated. Compound 1 showed remarkable inhibitory activity against phosphodiesterase-4 (PDE4D2), with an IC 50 value of 40 nM, which is 20-fold higher than that of the positive control (rolipram). Furthermore, compound 1 significantly inhibited tubulin polymerization.
■ INTRODUCTION
Selaginellin represents a structurally intriguing class of phenolic pigments featuring unique alkynyl and p-quinone methide functionalities, which have hitherto been found only in the genus Selaginella. 1 With their unique molecular architectures and compelling biological activities, selaginellin and its analogues have attracted great attention from the synthetic and pharmacological communities. 2−6 Specifically, four newly discovered selaginellin analogues with a fluorene core, namely, selaginpulvilins, separated from S. pulvinata, have been identified as natural inhibitors of PDE4D2. 7 Phosphodiesterase-4 (PDE4), which is predominantly expressed in most inflammatory and immune cells, is a hydrolytic enzyme responsible for the degradation of cyclic adenosine monophosphate (cAMP) and has been identified as a therapeutic target in tumors, 8 inflammatory diseases, 9 and the central nervous system. 10 Therefore, the search for new selaginellin analogues as inhibitors of PDE4 with powerful efficiency is fascinating.
Selaginella tamariscina, collected from Guangxi, has been widely used in traditional Chinese medicine for the treatment of hepatitis, hematuria, and traumatic injury. 11 Research toward the discovery of novel PDE4 inhibitors from this plant afforded two new (1, 2) and eight known selaginellin analogues (3−10) . To the best of our knowledge, 1 represents the first example of a selaginellin analogue characterized by a 1H-2-benzopyran core. Most of the isolates showed strong inhibitory activity against PDE4D2, and the most active, 1, significantly inhibited tubulin polymerization. In this article, the isolation, structural elucidation, plausible biosynthetic pathway, and biological evaluation of the isolated compounds are described. 5, 8, 12) to the quaternary carbon (δ C 89.2, C-7) indicate the presence of two geminal p-phenol groups at C-7. The alkenyl was linked to a p-phenol group by HMBCs from H-28 and H-32 to C-27, which was further placed at C-14 by HMBCs from H-26 to C-15 and C-19. The carboxyl and the last p-phenol group were located at C-15 and C-18 by HMBCs from H-16 to C-34 and H-20 and H-24 to C-18, respectively. The polysubstituted phenyl ring was further linked to C-7 by the observation of a weak J 4 HMBC from H-17 to C-7. 7 On account of the structure of 1 demanding an additional ring, the remaining oxygen was linked to C-7 and C-27 to form a pyran ring. This was supported by the 13 C NMR chemical shifts of C-7 and C-27, which were larger than normal. Therefore, according to the molecular composition of 1, a pyran ring attached by a polysubstituted phenyl ring to form a 1H-2-benzopyran core, as described in Figure 1 , was suggested for 1. The structure of selagintamarlin A described here represents a hitherto unknown selaginellin skeleton. Thus, a putative biogenetic pathway for 1 is proposed (Scheme 1) to assist further studies for biomimetic semisynthesis or total chemical synthesis. The most plausible biosynthetic precursor of 1 is selaginellin O (10). Selaginellin O is oxidized to form intermediate I, and hydration of I would generate intermediate II.
■ RESULTS AND DISCUSSION
12 The key step of this biosynthesis, the linkage of C 7 −OH and C-27 of intermediate II to afford 1, is probably due to the hydroxy group attacking the triple bond (shown as curved arrows in Scheme 1) to form a stable pyran ring.
All of the isolates were evaluated for their inhibitory activity against PDE4D2 and computational docking into the active site of PDE4D2. Compounds 1−10 potently inhibited the activity of PDE4D2, with IC 50 values in the range of 40−1680 nM. In particular, 1, the most active compound, showed an IC 50 of 40 nM, being 20-fold stronger than that of the positive control (Table 1 and Figure S9 ). The partition coefficient values of compounds 1−10 were calculated using the Marvin Sketch program, and the values (log D) of 1 at physiological pHs 3.0 and 7.4 were 6.86 and 3.60, respectively (Table S2 ). As shown in Figure 3a , compound 1, with the best docking score, was nicely bound to the active binding site and filled the cavity (Supporting Information S1).
Recent studies have suggested that PDE4 inhibitors have also been identified as a target agent for brain tumor therapy. 8 Hence, compounds 1−10 were tested for antitumor activity against MGC-803, HepG2, A549, NCI-H460, and SKOV-3 human cancer cell lines using the MTT method, with fluorouracil as the positive control. The results are expressed as IC 50 values, shown in Table S1 . Most of the isolates exhibited moderate antitumor activity, especially compound 1 (IC 50 values in the range of 7.02−10.32 μM).
It is worth noting that diarylacrylonitrile (CC-5079) can act as a dual inhibitor of PDE4 and tubulin polymerization. 13 Therefore, we also performed docking studies for compounds 1−10 to elucidate their structural basis. Surprisingly, the accommodation of compound 1 in the binding site is similar to that of colchicine, a well known tubulin polymerization inhibitor (Figure 3b,c) . Furthermore, we investigated whether compound 1 acts as an inhibitor of tubulin polymerization in a dose-dependent manner.
14 As shown in Figure 4 , for compound 1, an obvious inhibition of polymerization was observed at two concentrations, and the rate of assembly as well as the final amount of microtubules was lower than that of the control.
In conclusion, selagintamarlin A (1) is a 1H-2-benzopyran selaginellin analogue with an unprecedented skeleton isolated 
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Article from S. tamariscina. Selaginpulvilin E (2) is an analogue of selaginpulvilins A−D. 7 Their structures have been determined, and the formation of 1 and 2 was deduced from 10 and 7, respectively. The inhibitory activity of compounds 1−10 against PDE4D2 was deeply studied. Compound 1 showed remarkable inhibitory activity against PDE4D2 and tubulin polymerization, which indicated that 1 might be a dual inhibitor of PDE4D2 and tubulin polymerization.
■ EXPERIMENTAL SECTION
General Experimental Procedures. The NMR spectra were recorded in CD 3 OD on a Bruker 400 MHz instrument (Bruker, Karlsruhe, Germany), with tetramethylsilane as the internal standard. HRESIMS data were obtained from a Thermo-Scientific Exactive spectrometer. IR spectra (KBr) were recorded on a PerkinElmer Spectrum Two FT-IR spectrometer. Silica gel (200−300 mesh; Qingdao Marine Chemical Factory, China), MCI gel (CHP20, 75−150 μm; Mitsubishi Chemical Corporation, Japan), ODS (50 μm; YMC, Japan), and Sephadex LH-20 gel (Pharmacia Biotech, Sweden) were used for column chromatography. Thin-layer chromatography was carried out on GF254 plates (Qingdao Marine Chemical Factory). Preparative high-performance liquid chromatography (HPLC) was carried out using a Shimadzu LC-6AD (Shimadzu, Japan) instrument with a YMC-Pack ODS-A column (20 mm I.D. × 250 mm, S-5 μm, 12 nm) and an SPD-20A wavelength detector at 210 nm. HPLC solvents were obtained from Tedia Company, Inc.
Plant Material. The herb of S. tamariscina was purchased from Jingxi County, Guangxi Zhuang Autonomous Region, in July 2014. The plant was authenticated by Prof. Shao PDE4D2 Assay. Human recombinant (5 pg/μL); PDE4D2 (BPS Biosciences) was added to the wells of black 96-well nonbinding plates. Immediately, the protein was treated with the compound or vehicle control. The enzyme was incubated with the drug for 30 min prior to addition of 200 nM FAMcAMP (Molecular Devices) to each assay well. The plates were incubated for 1 h at room temperature. After incubation, the terbium (Tb)-based fluorescence intensity (FI) phosphodiesterase evaluation assay (Molecular Devices) binding reagent was added to each well, and the plates were incubated for an additional 1 h at room temperature. FI was measured according to the manufacturer's specifications using a TECAN plate reader. Each measurement was repeated at least three times. The IC 50 values were calculated by nonlinear regression. As a reference compound, rolipram purchased from Sigma was measured for its IC 50 value before the other assays. Tubulin Polymerization Assay in Vitro and Competitive Inhibition Assays. Tubulin polymerization was monitored by the change in optical density at 340 nm using a modification of methods described by Jordan et al. 15 A purified brain tubulin polymerization kit was purchased from Cytoskeleton (BK006P; Denver, CO). The final buffer concentrations for tubulin polymerization contained 80.0 mM piperazine-N,N′-bis(2-ethanesulfonic acid)sequisodium salt (pH 6.9), 2.0 mM MgCl 2 , 0.5 mM ethylene glycol bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid, 1 mM guanosine-5'-triphosphate, and 10.2% glycerol. Test compounds were added in different concentrations, and then, all components except the purified tubulin were warmed to 37°C. The reaction was initiated by the addition of tubulin to a final concentration of 3.0 mg/mL. Paclitaxel, CA-4, and phenstatin were used as positive controls under the same conditions. The optical density was measured for 1 h at 1 min intervals in BioTek's Synergy 4 multifunction microplate spectrophotometer with a temperature-controlled cuvette holder. Assays were performed according to the manufacturer's instructions and under conditions similar to those employed for the tubulin polymerization assays described above. 16, 17 Molecular Modeling. All the docking studies were carried out using Sybyl-X 2.0 on a windows workstation. The crystal structure of PDE4D2 18 and the tubulin in complex with colchicine (PDB: 3E22.pdb) 19−21 were retrieved from the RCSB Protein Data Bank. The isolated compounds were selected for the docking studies. The three-dimensional structures of these selected compounds were first built using Sybyl-X 2.0 sketch, followed by energy minimization using the MMFF94 force field and Gasteiger-Marsili charges. We employed Powell's method for optimizing the geometry with a distance-dependent dielectric constant and a termination energy gradient of 0.005 kcal/mol. All of the selected compounds were automatically docked into the colchicinebinding pocket of tubulin by an empirical scoring function and a patented search engine in the Surflex docking program. Before the docking process, the natural ligand was extracted; the water molecules were removed from the crystal structure. Subsequently, the protein was prepared using the Biopolymer module implemented in Sybyl. The polar hydrogen atoms were added. The automated docking manner was applied in the present work. Other parameters were established by default to estimate the binding affinity characterized by the Surflex-Dock scores in the software. Surflex-Dock total scores, which were expressed in −log 10 (Kd) units to represent binding affinities, were applied to estimate the ligand−receptor interactions of the newly designed molecules. A higher score represents a stronger binding affinity. The optimal binding pose of the docked compounds was selected on the basis of the Surflex scores and visual inspection of the docked complexes. 
